3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
39
Pancreatic Neoplasms
19
Stomach Neoplasms
13
Colonic Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Adenocarcinoma Of Esophagus
11
Rectal Neoplasms
10
Neoplasm Metastasis
10
Burkitt Lymphoma
10
Neoplasms
9
Esophageal Neoplasms
9
Cholangiocarcinoma
6
Adenocarcinoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Esophageal Squamous Cell Carcinoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Down Syndrome
2
Carcinoma, Renal Cell
2
Interventions
Nivolumab
3
tivozanib
1
regorafenib
1
neratinib
1
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
capivasertib
1
Valproic Acid
1
Thioctic Acid
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Gemcitabine
1
Fulvestrant
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Bortezomib
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Leucovorin
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts